Study Design: Participants who achieved average 20.9% weight loss on tirzepatide over 36 weeks were randomized to either: Continue tirzepatide Switch to placebo Results at 88 Weeks (52 weeks after randomization): Continued Tirzepatide: Additional 5.5% weight loss Total weight loss: 25.3% from baseline 89.5% maintained at least 80% of initial weight loss Switched to Placebo: 14% weight regain Total weight loss: 9.9% from baseline Only 16.6% maintained at least 80% of initial weight loss Key Takeaway: Continued treatment is essential for maintaining weight loss
It persists either in an oxidized state, known as GSSG, or in its most popularly known reduced state, called GSH
The table above illustrates why these two peptides are considered complementary rather than redundant
This is big news, and will likely pressure insurersand the governmentto widen its Wegovy coverage
Some users find that the combination helps them feel more in control of their dietary choices, making it easier to stick to a healthy eating plan
Despite significant progress, several limitations hinder widespread adoption and efficacy
.png)
